Navigation Links
Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study
Date:6/16/2009

ROCKVILLE, Md., June 16 /PRNewswire-USNewswire/ -- According to a new report by HHS' Agency for Healthcare Research and Quality, there is insufficient evidence to conclude that genetic testing for two gene mutations in adults with a history of blood clots helps to prevent a condition known as deep-vein thrombosis or to improve other clinical outcomes.

The report, a summary of which will be published in the June 17 issue of JAMA, also failed to find any benefit from genetic testing of family members of patients who have at least one of the two mutations -- known as Factor V Leiden (FVL) and prothrombin G20210A -- as well as a history of deep-vein thrombosis.

As many as 600,000 Americans each year may have deep-vein thrombosis -- blood clots that form in the legs or pelvis. The condition occurs most commonly in people who are sedentary for a long period of time, such as when recovering from surgery or traveling long distances. The true number of people who develop a pulmonary embolism is unknown, but AHRQ data for hospital patients show that 258,000 individuals were diagnosed with the condition in 2006, and 20,000 died as a result.

"While genetic testing shows great promise to improve treatment and prevent disease, this report clearly shows that we need more research and evidence to achieve its full potential," said AHRQ Director Carolyn M. Clancy, M.D. "But people can help reduce their likelihood of developing a blood clot by talking with their doctor about precautions."

The evidence report was requested and supported by the Office of Public Health Genomics (OPHG) at HHS' Centers for Disease Control and Prevention. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, established by OPHG in 2005, will use this evidence report and other evidence to make recommendations on the validity and utility of genetic tests for FVL and prothrombin G20210A. This report, titled Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism, is the fifth evidence report requested for EGAPP.

The authors, who were led by Jodi Segal, M.D., of the AHRQ-supported Johns Hopkins Evidence-based Practice Center in Baltimore, failed to find any studies that directly addressed the effect of genetic testing on patient outcomes, but they found research indicating that keeping patients who have a genetic tendency to develop blood clots on blood-thinning drugs such as warfarin reduces the chance of a future clot. This benefit appears to be similar to that seen in patients who do not have the genetic tendency to develop blood clots but who have a history of clots.

The authors also reviewed the evidence for the accuracy of the testing methods used to identify the FVL and prothrombin G20210A mutations, which can signal continued risk of blood clots. The evidence shows that tests for identifying the mutations have excellent analytic validity and that nearly all laboratories report accurate results.

The authors called for randomized trials with sufficiently large sample sizes and long-term follow-up, as well as other research to determine whether changing provider practice based on genetic test results improves patient outcomes.

Once the embargo lifts on June 16 at 4:00 p.m. EDT, AHRQ's evidence report will be available at http://www.ahrq.gov/downloads/pub/evidence/pdf/factorvleiden/fvl.pdf. For more AHRQ information on deep-vein thrombosis, see Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement, and Your Guide to Preventing and Treating Blood Clots, available in both English and Spanish. Free, single copies of all AHRQ publications are available by calling the AHRQ Publications Clearinghouse at (800) 358-9295 or by sending an e-mail to AHRQPubs@ahrq.hhs.gov.

Use Twitter to get AHRQ news updates: www.twitter.com/ahrqnews.


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
2. Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed
3. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
4. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
5. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
6. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
7. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
8. Industry Executives Finding Value in Shift of Scientific Publications
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
11. Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
(Date:5/6/2017)... 5, 2017  May is Stroke Awareness Month and ... most important methods to prevent a stroke: monitor and ... Disease Control and Prevention, undetected and uncontrolled hypertension is ... the global leader in personal heart health technology, recently ... heart attack and stroke and is advancing a national ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original ... discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget ... a fidget toy to the market that was made of superior quality and wouldn’t ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... ... FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his faith ... published authors, Bob and Margaret Massey. Bob Massey is small in stature but big ... tough." His love for others is apparent in all of his life decisions. ...
Breaking Medicine News(10 mins):